(Q37729239)

22 August 2017

Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies (English)

1 reference

22 August 2017

1 reference

Yanfang Jiang

1

1 reference

22 August 2017

Wanyu Li

2

1 reference

22 August 2017

Lei Yu

3

1 reference

22 August 2017

Jingjing Liu

4

1 reference

22 August 2017

Guijie Xin

5

1 reference

22 August 2017

Hongqing Yan

6

1 reference

22 August 2017

Pinghui Sun

7

1 reference

22 August 2017

Hong Zhang

8

1 reference

22 August 2017

Damo Xu

9

1 reference

22 August 2017

Junqi Niu

10

1 reference

22 August 2017

4 October 2010

1 reference

Cellular and Molecular Immunology

22 August 2017

1 reference

22 August 2017

8

1 reference

22 August 2017

1

1 reference

22 August 2017

75-82

1 reference

https://scigraph.springernature.com/pub.10.1038/cmi.2010.37

22 August 2017

0 references

cites work

Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4002983

Ribavirin and IFN-alpha combination therapy induces CD4+ T-cell proliferation and Th1 cytokine secretion in patients with chronic hepatitis B

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4002983

Regulatory T cells in viral hepatitis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4002983

Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4002983

CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4002983

Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression?

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4002983

The immune response induced by hepatitis B virus principal antigens.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4002983

The immune response during hepatitis B virus infection

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4002983

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4002983

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4002983

Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4002983

Cytotoxic T cells and viral hepatitis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4002983

The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4002983

Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4002983

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4002983

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4002983

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4002983

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4002983

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4002983

Flow cytometric detection of intracellular TH1/TH2 cytokines using whole blood: validation of immunologic biomarker for use in epidemiologic studies

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4002983

Neonatal Tolerance Revisited: Turning on Newborn T Cells with Dendritic Cells

1 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FCMI.2010.37

21 January 2018

1 reference

12 December 2020

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

PubMed

12 December 2020

Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B

1 reference

PubMed

12 December 2020

Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B

1 reference

PubMed

12 December 2020

Identifiers

DOI

10.1038/CMI.2010.37

1 reference

22 August 2017

1 reference

22 August 2017

PubMed publication ID

20921939

1 reference